Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: BioLife develops and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol, CryoStor, BloodStor) for cells, tissues, and organs. The company serves cell therapy firms, pharmaceutical companies, and cord blood banks.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenue | $610,799 | $512,909 |
| Gross Profit | $242,199 | $238,720 |
| Gross Margin | 39.7% | 46.6% |
| Operating Loss | $(454,277) | $(393,814) |
| Net Loss | $(630,122) | $(531,776) |
| Cash and Equivalents (End of Period) | $35,097 | $2,292 |
| Working Capital | $453,041 | $474,271 |
| Total Liabilities | $11,486,656 | $10,857,971 |
| Accumulated Deficit | $(52,824,973) | $(52,194,852) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% ($97,890) driven by higher average selling prices on flagship products, sales to new customers, and a significant increase in distributor sales.
- Margin Compression: Gross margin declined from 46.6% to 39.7%. This was primarily due to non-recurring costs related to employee transitions and $25,847 in expired inventory. Management notes that excluding one-time adjustments, the margin would have been 42.6%.
- Expense Increases:
- R&D: Increased 137% ($91,861) due to higher legal/consulting fees and added personnel.
- Interest Expense: Increased to $160,542 from $136,372 due to a higher debt balance.
- Expense Decreases: Sales and marketing expenses decreased 32% ($39,720) due to lower personnel costs.
- Cash Flow: Net cash used in operating activities improved to $(304,639) from $(377,476). Financing activities provided $350,000 via related-party loans.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The company has an accumulated deficit of approximately $53 million and has been unable to generate sufficient income to meet operating needs. This raises substantial doubt about its ability to continue as a going concern.
- Liquidity Strategy: Management believes access to "Facility Agreements" (loans from shareholders Thomas Girschweiler and Walter Villiger) combined with customer collections will fund operations through September 30, 2011. Additional capital will be required if these facilities are restricted or terminated.
- Recent Developments:
- Initial shipments to a new contract manufacturing customer.
- Product shipments supporting a Phase II clinical study for a cell-based regenerative medicine therapy.
- Launch of CryoStor CS10 in a new sterile, single-use vial format.
- Contingencies: The company is subject to five complaints filed by former employees in New York. No accrual has been made for litigation outcomes as of March 31, 2011.
- Subsequent Event: An additional $210,000 was received from related parties after the period end.
Investor Verification Checklist
- Debt Sustainability: Verify the terms and availability of the "Facility Agreements" with related parties, as the company relies on them for immediate survival.
- Margin Normalization: Confirm whether the gross margin decline was truly due to one-time inventory write-offs or indicative of structural cost issues.
- Litigation Exposure: Review the status of the five pending employee complaints to assess potential financial impact.
- Cash Runway: Validate the projection that current cash and financing access will sustain operations through September 2011.
- Dilution Risk: Assess the potential for dilutive financing if the related-party loans are terminated or insufficient.